Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
NeuroBo Pharmaceuticals, Inc. (NRBO) had Non-Operating Income/Expense of $3.42M for the most recently reported fiscal year, ending 2023-12-31.
Income Statement Financials | |
-- |
|
$-12.47M |
|
-- |
|
-- |
|
$15.89M |
|
$-15.89M |
|
Non-Operating Income/Expense |
$3.42M |
$-12.47M |
|
$-12.47M |
|
$-12.47M |
|
$-12.47M |
|
$-12.47M |
|
$-12.47M |
|
$-15.89M |
|
$-15.88M |
|
5.07M |
|
5.07M |
|
$-2.46 |
|
$-2.46 |
|
Balance Sheet Financials | |
$22.51M |
|
$0.05M |
|
$0.27M |
|
$22.78M |
|
$5.96M |
|
-- |
|
$0.14M |
|
$6.10M |
|
$16.68M |
|
$16.68M |
|
$16.68M |
|
4.91M |
|
Cash Flow Statement Financials | |
$-10.80M |
|
$-0.05M |
|
$-0.08M |
|
$33.36M |
|
$22.43M |
|
$-10.93M |
|
$0.22M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
3.78 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.85M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-74.74% |
|
-74.74% |
|
-54.74% |
|
-74.74% |
|
$3.40 |
|
$-2.14 |
|
$-2.13 |